JO
DRMA icon

John Overdeck’s Dermata Therapeutics DRMA Stock Holding History

John Overdeck’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8
Closed -$33K – 3107
2021
Q4 		$33K Buy
+8
New +$70.7K ﹤0.01% 4161

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

John Overdeck's DRMA Position: Q1 2022 in Review

John Overdeck sold out of Dermata Therapeutics (DRMA) in Q1 2022, closing a stake of 8 shares — an estimated $33K sold.

John Overdeck first reported a position in DRMA in Q4 2021 and held it in 1 quarter. The position peaked at $33K in Q4 2021. 6 funds tracked by Wall St. Rank hold DRMA as of Q1 2022.

  • John Overdeck reported no remaining Dermata Therapeutics position as of Q1 2022 after selling out during the quarter.
  • John Overdeck sold 8 Dermata Therapeutics shares in Q1 2022, an estimated $33K.
  • John Overdeck first reported a position in Dermata Therapeutics in Q4 2021 and held it in 1 quarter.
  • John Overdeck's Dermata Therapeutics position peaked at $33K in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2022.

Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.